[{"id":"33062010-2f9f-457a-bb48-293b21b77b51","acronym":"RAGNAR","url":"https://clinicaltrials.gov/study/NCT04083976","created_at":"2021-01-18T19:59:45.508Z","updated_at":"2025-02-25T12:37:25.290Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations","source_id_and_acronym":"NCT04083976 - RAGNAR","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR2 • FGFR • TACC3 • TACC2","pipe":" | ","alterations":" FGFR3 mutation • FGFR mutation • FGFR fusion","tags":["FGFR2 • FGFR • TACC3 • TACC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 mutation • FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 11/20/2019","start_date":" 11/20/2019","primary_txt":" Primary completion: 12/04/2023","primary_completion_date":" 12/04/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"ab21b4e4-b3ac-475c-9005-48c011e2a7c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05316155","created_at":"2022-04-07T12:57:01.192Z","updated_at":"2025-02-25T15:27:19.690Z","phase":"Phase 1/2","brief_title":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","source_id_and_acronym":"NCT05316155","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib) • erdafitinib intravesical delivery system (TAR-210)"],"overall_status":"Recruiting","enrollment":" Enrollment 262","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 03/30/2028","primary_completion_date":" 03/30/2028","study_txt":" Completion: 09/19/2029","study_completion_date":" 09/19/2029","last_update_posted":"2025-02-10"},{"id":"25d363db-b73d-42b4-a08a-717568224b15","acronym":"THOR-2","url":"https://clinicaltrials.gov/study/NCT04172675","created_at":"2021-01-18T20:21:16.432Z","updated_at":"2025-02-25T17:00:18.386Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","source_id_and_acronym":"NCT04172675 - THOR-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Balversa (erdafitinib) • mitomycin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 02/28/2020","start_date":" 02/28/2020","primary_txt":" Primary completion: 07/12/2024","primary_completion_date":" 07/12/2024","study_txt":" Completion: 03/03/2025","study_completion_date":" 03/03/2025","last_update_posted":"2025-02-03"},{"id":"7bb8b08e-5d1b-431b-b5ae-8689cf85f453","acronym":"","url":"https://clinicaltrials.gov/study/NCT05656235","created_at":"2024-01-16T22:19:54.900Z","updated_at":"2025-02-25T15:36:00.703Z","phase":"Phase 2","brief_title":"Renal Retention in High Grade Upper Tract Urothelial Cancer","source_id_and_acronym":"NCT05656235","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/25/2024","start_date":" 11/25/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-12-11"},{"id":"0b4bc025-bfab-4d27-a83b-163254f008e0","acronym":"CR109248","url":"https://clinicaltrials.gov/study/NCT05567185","created_at":"2022-10-05T13:56:18.093Z","updated_at":"2024-07-02T16:35:02.053Z","phase":"Phase 1","brief_title":"A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer","source_id_and_acronym":"NCT05567185 - CR109248","lead_sponsor":"Janssen Pharmaceutical K.K.","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erdafitinib intravesical delivery system (TAR-210)"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 10/16/2026","primary_completion_date":" 10/16/2026","study_txt":" Completion: 09/24/2027","study_completion_date":" 09/24/2027","last_update_posted":"2024-05-22"},{"id":"b2993259-256a-4604-9f68-777de564f0ad","acronym":"FOENIX-CCA2","url":"https://clinicaltrials.gov/study/NCT02052778","created_at":"2021-01-17T17:33:24.806Z","updated_at":"2024-07-02T16:35:13.841Z","phase":"Phase 1/2","brief_title":"A Study of TAS-120 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02052778 - FOENIX-CCA2","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion • FGFR3 mutation • FGFR fusion • FGFR2 rearrangement • FGFR3 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR3 mutation • FGFR fusion • FGFR2 rearrangement • FGFR3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Completed","enrollment":" Enrollment 407","initiation":"Initiation: 07/21/2014","start_date":" 07/21/2014","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 05/29/2021","study_completion_date":" 05/29/2021","last_update_posted":"2024-03-20"},{"id":"c92b8794-1c47-49f1-88e3-148924bb13cc","acronym":"BISCAY","url":"https://clinicaltrials.gov/study/NCT02546661","created_at":"2021-01-18T12:19:22.211Z","updated_at":"2024-07-02T16:35:15.193Z","phase":"Phase 1","brief_title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT02546661 - BISCAY","lead_sponsor":"AstraZeneca","biomarkers":" HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL","pipe":" | ","alterations":" PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification","tags":["HRD • CDKN2A • RB1 • FGFR • CD8 • CCNE1 • MYCN • IFNG • IL6 • IL2 • IL10 • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 10/03/2016","start_date":" 10/03/2016","primary_txt":" Primary completion: 03/18/2020","primary_completion_date":" 03/18/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-12"},{"id":"1d4ba0e5-2e91-4eb0-9b78-dcfdf4bea1c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564416","created_at":"2022-10-03T15:56:45.916Z","updated_at":"2024-07-02T16:35:16.428Z","phase":"Phase 2","brief_title":"Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial","source_id_and_acronym":"NCT05564416","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • FGFR3","pipe":" | ","alterations":" FGFR fusion","tags":["PD-L1 • FGFR3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • Balversa (erdafitinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/12/2023","start_date":" 10/12/2023","primary_txt":" Primary completion: 11/03/2023","primary_completion_date":" 11/03/2023","study_txt":" Completion: 11/03/2023","study_completion_date":" 11/03/2023","last_update_posted":"2024-03-05"},{"id":"1f885c20-bddc-441e-b3b3-ce916b0c4eaf","acronym":"FIGHT-209","url":"https://clinicaltrials.gov/study/NCT05267106","created_at":"2022-03-04T15:53:30.724Z","updated_at":"2024-07-02T16:35:22.897Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations","source_id_and_acronym":"NCT05267106 - FIGHT-209","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-01-19"},{"id":"fc5e8b29-6dcb-4531-a767-ace8038c4ef9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02272998","created_at":"2021-01-18T10:41:33.356Z","updated_at":"2024-07-02T16:35:36.656Z","phase":"Phase 2","brief_title":"Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.","source_id_and_acronym":"NCT02272998","lead_sponsor":"Sameek Roychowdhury","biomarkers":" FLT3 • ABL1 • RET • PDGFRA • FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FLT3 • ABL1 • RET • PDGFRA • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/24/2015","start_date":" 02/24/2015","primary_txt":" Primary completion: 11/17/2022","primary_completion_date":" 11/17/2022","study_txt":" Completion: 11/17/2023","study_completion_date":" 11/17/2023","last_update_posted":"2023-09-18"},{"id":"ebd5d4f3-9c51-4862-880f-738277ea8dc8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05216120","created_at":"2022-02-05T18:27:56.347Z","updated_at":"2024-07-02T16:35:44.081Z","phase":"Phase 2","brief_title":"Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas","source_id_and_acronym":"NCT05216120","lead_sponsor":"HonorHealth Research Institute","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2023-07-03"},{"id":"819807a7-627e-40e5-a967-fc5eec1c4f69","acronym":"TARGET","url":"https://clinicaltrials.gov/study/NCT02824133","created_at":"2021-01-18T13:50:52.751Z","updated_at":"2024-07-02T16:36:59.263Z","phase":"Phase 1/2","brief_title":"Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion\"","source_id_and_acronym":"NCT02824133 - TARGET","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" FGFR • TACC3 • TACC1","pipe":" | ","alterations":" FGFR fusion • FGFR1 fusion • FGFR3 fusion • FGFR1 expression • TACC3 expression • FGFR3 expression • FGFR1-TACC1 fusion","tags":["FGFR • TACC3 • TACC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR fusion • FGFR1 fusion • FGFR3 fusion • FGFR1 expression • TACC3 expression • FGFR3 expression • FGFR1-TACC1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fexagratinib (ABSK091)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2019-05-29"}]